Neuphoria Therapeutics Inc. is a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need. Its lead drug candidate, BNC210, is an oral, proprietary, selective negative allosteric modulator of the Î±7 nicotinic acetylcholine receptor, for the acute, as-needed treatment of social anxiety disorder and for the chronic treatment of post-traumatic stress disorder. BNC210 is a well-tolerated, broad-spectrum antianxiety experimental therapeutic, designed to restore neurotransmitter balance in relevant brain areas, providing rapid relief from stress and anxiety symptoms without the common pitfalls of sedation, cognitive impairment, or addiction. In addition, the Company has two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimerâ€™s disease and other central nervous system conditions.

Employees

Sector

Biotechnology & Medical Research

More about the company

Market Cap	21.58M 15.02M 13.38M 12.24M 11.15M 21.01M 1.42B 147M 58.8M 752M 56.36M 55.15M 2.37B	P/E 2027 *	-1.14x	P/E 2028 *	-1.13x
Enterprise Value	21.58M 15.02M 13.38M 12.24M 11.15M 21.01M 1.42B 147M 58.8M 752M 56.36M 55.15M 2.37B	EV / Sales 2027 *	-	EV / Sales 2028 *	-
Free-Float	94.98%	Yield 2027 *	-	Yield 2028 *	-

10-10	EARNINGS AND TRADING: Mincon says 2026 results to beat expectations	AN
09-19	Neuphoria Therapeutics Inc. Reports Earnings Results for the Full Year Ended June 30, 2026	CI
07-24	Scancell Holdings plc executed a term sheet to acquire Neuphoria Therapeutics Inc.(NasdaqGM:NEUP) for $35 million.	CI
07-23	Neuphoria Therapeutics Agrees to All-Share Takeover by Scancell	MT
07-23	Scancell agrees to buy Neuphoria, combined firm set to list on Nasdaq	AN
07-23	Stocks down as eurozone rate call nears	AN
07-23	Scancell, Neuphoria Therapeutics Agree All-share Merger	MT
06-27	Neuphoria Confirms Business Combination Talks With Scancell	MT
06-27	Neuphoria Responds to the Announcement Made by London-Listed Scancell Holdings plc	CI
06-26	Scancell Confirms Advanced Talks for Potential Acquisition of Nasdaq-listed Neuphoria Therapeutics	MT
06-26	Scancell confirms advanced talks on takeover of Neuphoria; eyes Nasdaq	AN
06-26	Scancell Confirms Advanced Talks over Reverse Merger with Neuphoria	CI
05-15	Neuphoria Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2026	CI

11-13	Neuphoria Files a Preliminary Proxy Statement with Securities and Exchange Commission	CI
11-11	Neuphoria announces initiation of strategic review	RE
22/10/25	Top Midday Decliners	MT
21/10/25	Neuphoria Therapeutics Provides Update on Affirm-1 Phase 3 Trial Evaluating BNC210 for the Acute Treatment of Social Anxiety Disorder	CI

07-23	Scancell and Neuphoria Therapeutics Announce Merger Agreement and Financing	AQ
06-29	Neuphoria responds to the announcement made by London-listed Scancell Holdings plc	AQ
06-27	Neuphoria Responds to the announcement made by London-listed Scancell Holdings plc	AQ
12-08	Leading Proxy Advisory Firm ISS Recommends that Shareholders Vote the WHITE Proxy Card FOR Both of Neuphoria’s Director Nominees	AQ
12-04	Neuphoria Responds to Lynx1’s Revised Indication of Interest at a Reduced Price and Premium	AQ

3 years	0.18	4.73
5 years	0.18	22
10 years	0.18	22

BIONOMICSSADR Stock Nasdaq

Stocks

BNOX

US09063M2052

Biotechnology & Medical Research

Valuation: BIONOMICSSADR

Latest news: BIONOMICSSADR

Analysts' recommendations: BIONOMICSSADR

Press Releases: BIONOMICSSADR

Quotes and Performance

Price Extremes

Other Biotechnology & Medical Research

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BIONOMICSSADR	+4.20%	-.--%	-	-	16.13M
WUXI APPTEC CO., LTD.	+3.80%	+8.10%	+63.78%	+77.70%	66.87B
ARGENX SE	+0.07%	+1.39%	+12.75%	+75.17%	57.2B
LONZA GROUP AG	+1.63%	+4.93%	+24.89%	+104.31%	56.55B
IQVIA HOLDINGS INC.	+0.41%	-3.70%	+26.06%	+34.32%	43.47B
BEONE MEDICINES AG	+2.51%	+4.22%	+20.49%	+110.71%	42.95B
REVOLUTION MEDICINES, INC.	-11.04%	-6.63%	+199.38%	+701.67%	42.8B
CELLTRION, INC.	+7.50%	+13.58%	+29.07%	+64.46%	34.01B
GENMAB A/S	+1.59%	-4.04%	+97.66%	+79.95%	32.11B
WUXI BIOLOGICS (CAYMAN) INC.	-2.55%	+6.65%	+35.54%	-5.31%	25.27B
Average	+0.81%	+3.06%	+56.62%	+138.11%	44.58B
Weighted average by Cap.	+0.61%	+3.42%	+54.76%	+140.32%

	2027 *	2028 *
Net sales	-	-
Net income	-24.59M -17.12M -15.25M -13.95M -12.7M -23.95M -1.62B -168M -67.02M -857M -64.24M -62.86M -2.7B	-29.17M -20.3M -18.09M -16.55M -15.07M -28.4M -1.92B -199M -79.48M -1.02B -76.19M -74.56M -3.21B
Net Debt	-	-